- Home
- FMNB vs URGN Comparison
FMNB vs URGN Comparison
Compare FMNB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMNB
- URGN
- Stock Information
- Founded
- FMNB 1887
- URGN 2004
- Country
- FMNB United States
- URGN United States
- Employees
- FMNB N/A
- URGN N/A
- Industry
- FMNB Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- FMNB Finance
- URGN Health Care
- Exchange
- FMNB Nasdaq
- URGN Nasdaq
- Market Cap
- FMNB 493.8M
- URGN 465.9M
- IPO Year
- FMNB N/A
- URGN 2017
- Fundamental
- Price
- FMNB $11.96
- URGN $10.15
- Analyst Decision
- FMNB Hold
- URGN Strong Buy
- Analyst Count
- FMNB 3
- URGN 6
- Target Price
- FMNB $16.33
- URGN $40.75
- AVG Volume (30 Days)
- FMNB 101.1K
- URGN 416.8K
- Earning Date
- FMNB 04-23-2025
- URGN 05-12-2025
- Dividend Yield
- FMNB 5.53%
- URGN N/A
- EPS Growth
- FMNB N/A
- URGN N/A
- EPS
- FMNB 1.22
- URGN N/A
- Revenue
- FMNB $162,118,000.00
- URGN $90,398,000.00
- Revenue This Year
- FMNB $15.83
- URGN $38.65
- Revenue Next Year
- FMNB $4.94
- URGN $118.69
- P/E Ratio
- FMNB $10.08
- URGN N/A
- Revenue Growth
- FMNB N/A
- URGN 9.29
- 52 Week Low
- FMNB $11.55
- URGN $9.03
- 52 Week High
- FMNB $16.32
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- FMNB 26.79
- URGN 42.34
- Support Level
- FMNB $12.86
- URGN $11.12
- Resistance Level
- FMNB $13.50
- URGN $11.40
- Average True Range (ATR)
- FMNB 0.40
- URGN 0.61
- MACD
- FMNB -0.07
- URGN -0.14
- Stochastic Oscillator
- FMNB 4.81
- URGN 14.77
About FMNB Farmers National Banc Corp.
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of company's revenue is derived from the bank segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.